The -2518 A/G MCP-1 polymorphism as a risk factor of inflammatory bowel disease

Pol Przegl Chir. 2012 May;84(5):238-41. doi: 10.2478/v10035-012-0039-7.

Abstract

Inflammatory bowel diseases (IBD) are disorders originated from immune disturbances. The AIM OF THE STUDY was to evaluate the association between the -2518 A/G MCP-1 polymorphism and the risk of IBD development.

Material and methods: Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Study group consisted of 197 subjects with IBD (120 with ulcerative colitis and 77 with Crohn's disease) as well as 210 healthy controls.

Results: The presence of the -2518 G/G MCP-1 genotype in the investigated groups seems to be connected with higher risk of inflammatory bowel disease as well as Crohn's disease only (OR 2.26; 95% CI 1.44-3.54 and OR 2.08; 95% CI 1.21-3.46, respectively).

Conclusions: Our data showed that the -2518 A/G MCP-1 polymorphism might be associated with the IBD occurrence and might be used as predictive factor of these diseases in a Polish population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Causality
  • Chemokine CCL2 / genetics*
  • Crohn Disease / epidemiology
  • Crohn Disease / genetics*
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Incidence
  • Inflammatory Bowel Diseases / epidemiology
  • Inflammatory Bowel Diseases / genetics*
  • Male
  • Middle Aged
  • Poland / epidemiology
  • Polymorphism, Single Nucleotide*
  • Risk Factors
  • White People / genetics*

Substances

  • CCL2 protein, human
  • Chemokine CCL2